Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China

被引：28

作者：

Li, Mingzhu ^{[1
]}

Zhao, Chao ^{[1
]}

Zhao, Yun ^{[1
]}

Li, Jingran ^{[1
]}

Wei, Lihui ^{[1
]}

机构：

[1] Peking Univ, Dept Obstet & Gynecol, Peoples Hosp, Beijing, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷

关键词：

immunogenicity; efficacy; safety; human papillomavirus vaccine; China;

D O I：

10.3389/fimmu.2023.1112750

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The incidence rate and mortality rate of cervical cancer have steadily increased in young women in China. Therefore, it is critical to improve HPV vaccination rates, particularly for the younger population. There are currently five types of prophylactic vaccines in China: bivalent HPV vaccine (AS04-HPV-16/18), quadrivalent HPV vaccine, 9-valent HPV vaccine, homemade Escherichia coli-produced HPV bivalent vaccine, and Pichia pastoris produced HPV bivalent vaccine. All these five HPV vaccines have completed relevant clinical trials in China, and have been proven to be generally well-tolerated and immunogenic, efficacious against persistent HPV-related infections and genital precancerous lesions (data for 9-valent HPV vaccine is absent), and have demonstrated acceptable safety profiles, as previously shown in global studies. Given that the HPV vaccination rate in China is still very low, additional HPV vaccine coverage is needed to reduce the incidence and mortality rates of cervical cancer.

引用

页数：5

共 22 条

[1] Trends in Cervical Cancer in Young Women in Hubei, China [J].

Cai, Hong-Bing ;

Liu, Xiao-Mei ;

Huang, Yi ;

Li, Xiao-Nan ;

Lie, Dao-Mei ;

Zhou, Quan ;

Pan, Feng-Lian ;

Wang, Zu-Hui ;

Li, Zhi-Yin ;

Wang, Xiao-Yan ;

Dai, Yin .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (07) :1240-1243

[2] Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages [J].

Chen, Qi ;

Zhao, Hui ;

Yao, Xingmei ;

Lin, Zhijie ;

Li, Juan ;

Lin, Bizhen ;

Wang, Rui ;

Huang, Yue ;

Su, Yingying ;

Wu, Ting ;

Li, Changgui ;

Pan, Huirong ;

Huang, Shoujie ;

Zhang, Jun ;

Xia, Ningshao .

VACCINE, 2020, 38 (39) :6096-6102

[3] Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up [J].

Chen, Wen ;

Zhao, Yun ;

Xie, Xing ;

Liu, Jihong ;

Li, Jingran ;

Zhao, Chao ;

Wang, Shaoming ;

Liao, Xueyan ;

Shou, Qiong ;

Zheng, Minghuan ;

Saah, Alfred J. ;

Wei, Lihui ;

Qiao, Youlin .

VACCINE, 2019, 37 (06) :889-897

[4] Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18 [J].

Chen, Wen ;

Zhang, Xun ;

Molijn, Anco ;

Jenkins, David ;

Shi, Ju-Fang ;

Quint, Wim ;

Schmidt, Johannes E. ;

Wang, Ping ;

Liu, Yu-Ling ;

Li, Lian-Kun ;

Shi, Hong ;

Liu, Ji-Hong ;

Xie, Xing ;

Niyazi, Mayinuer ;

Yang, Pei ;

Wei, Li-Hui ;

Li, Long-Yu ;

Li, Jie ;

Liu, Jin-Feng ;

Zhou, Qi ;

Hong, Ying ;

Li, Li ;

Li, Qing ;

Zhou, Hong-Lin ;

Bian, Mei-Lu ;

Chen, Jing ;

Qiao, You-Lin ;

Smith, Jennifer S. .

CANCER CAUSES & CONTROL, 2009, 20 (09) :1705-1713

[5]

Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1

[6] A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China [J].

Hu, Shangying ;

Xu, Xiaoqian ;

Zhang, Yanyang ;

Liu, Yawen ;

Yang, Chunxia ;

Wang, Yueyun ;

Wang, Yan ;

Yu, Yanqin ;

Hong, Ying ;

Zhang, Xingxing ;

Bian, Rui ;

Cao, Xian ;

Xu, Lili ;

Zhao, Fanghui .

VACCINE, 2021, 39 (01) :35-44

[7] Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial [J].

Hu, Shangying ;

Xu, Xiaoqian ;

Zhu, Fengcai ;

Hong, Ying ;

Hu, Yuemei ;

Zhang, Xun ;

Pan, Qinjing ;

Zhang, Wenhua ;

Zhang, Chengfu ;

Yang, Xiaoping ;

Yu, Jiaxi ;

Zhu, Jiahong ;

Zhu, Yejiang ;

Chen, Feng ;

Zhao, Shuang ;

Karkada, Naveen ;

Tang, Haiwen ;

Bi, Dan ;

Struyf, Frank ;

Zhao, Fanghui .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) :955-964

[8] Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women [J].

Hu, Yue-Mei ;

Guo, Meng ;

Li, Chang-Gui ;

Chu, Kai ;

He, Wen-Gang ;

Zhang, Jing ;

Gu, Jian-Xiang ;

Li, Juan ;

Zhao, Hui ;

Wu, Xiang-Hong ;

Lin, BiZhen ;

Lin, Zhi-Jie ;

Yao, Xing-Mei ;

Li, Ya-Fei ;

Wei, FeiXue ;

Huang, Yue ;

Su, Ying-Ying ;

Zhu, Feng-Cai ;

Huang, Shou-Jie ;

Pan, Hui-Rong ;

Wu, Ting ;

Zhang, Jun ;

Xia, Ning-Shao .

SCIENCE CHINA-LIFE SCIENCES, 2020, 63 (04) :582-591

[9] Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females [J].

Li, Rongcheng ;

Li, Yanping ;

Radley, David ;

Liu, Youping ;

Huang, Teng ;

Sings, Heather L. ;

Zhang, Lingling ;

Wang, Wei ;

Zhong, Xiang ;

Saah, Alfred J. .

VACCINE, 2012, 30 (28) :4284-4291

[10] Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study [J].

Lv, Huakun ;

Wang, Shenyu ;

Liang, Zhenzhen ;

Yu, Wei ;

Yan, Chuanfu ;

Chen, Yingping ;

Hu, Xiaosong ;

Fu, Rong ;

Zheng, Minghuan ;

Group, Thomas ;

Luxembourg, Alain ;

Liao, Xueyan ;

Chen, Zhiping .

VACCINE, 2022, 40 (23) :3263-3271

← 1 2 3 →